David N. Gordon - 13 Jul 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Reporting relationship: Chief Medical Officer
Issuer ticker: ACRS
Reported as of: 13 Jul 2021
Net transaction value: -$44,675
SEC form: 4
Accepted by SEC: 14 Jul 2021, 17:32:17 UTC
Prior SEC filing: 07 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ Mark Ballantyne, Attorney-in-Fact

Filing notes and source

Key filing fact

David N. Gordon filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 14 Jul 2021.

Key facts

This page summarizes David N. Gordon's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Jul 2021, 17:32.

Change

Previous filing in this sequence was filed on 07 Jul 2021.
Current net transaction value: -$44,675.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRS transaction

Common Stock

Sale

Transaction value: $44,675
Shares: -2,631
Change %: -1.8%
Price: $16.98
Shares after: 147,447
Date: 13 Jul 2021
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on July 2, 2021 pursuant to preexisting sell-to-cover elections.

Footnote F2

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.9755 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.